DNA-Matched drugs may outperform standard care for advanced cancer
NCT ID NCT07346209
First seen Jan 27, 2026 · Last updated Apr 30, 2026 · Updated 14 times
Summary
This study tests whether drugs chosen based on a patient's tumor DNA mutations can delay cancer growth longer than standard treatments. About 280 adults with metastatic or unresectable solid cancers will be randomly assigned to either personalized drugs or usual care. Participants visit the clinic every two months for checkups and scans to track tumor progression.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California, San Diego
La Jolla, California, 92093, United States
Conditions
Explore the condition pages connected to this study.